Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist

Documenti analoghi

• Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis
  di: Opal, SM, et al.
  Pubblicazione: (2009)
• Inhibition of Corneal Inflammation by the TLR4 Antagonist Eritoran Tetrasodium (E5564)
  di: Sun, Yan, et al.
  Pubblicazione: (2008)
• Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
  di: Nagy, CF, et al.
  Pubblicazione: (2011)
• Eritoran tetrasodium (E5564) Treatment for Sepsis: Review of Preclinical and Clinical Studies
  di: Barochia, Amisha, et al.
  Pubblicazione: (2011)
• Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis(*)
  di: Barochia, Amisha V., et al.
  Pubblicazione: (2010)